Acuta Capital Partners as of Dec. 31, 2017
Portfolio Holdings for Acuta Capital Partners
Acuta Capital Partners holds 63 positions in its portfolio as reported in the December 2017 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Immunomedics | 20.6 | $109M | 6.8M | 16.16 | |
| Assembly Biosciences | 9.3 | $49M | 1.1M | 45.25 | |
| iShares Russell 2000 Index (IWM) | 7.2 | $38M | 250k | 152.46 | |
| Iovance Biotherapeutics (IOVA) | 5.9 | $31M | 3.9M | 8.00 | |
| SPDR S&P Biotech (XBI) | 5.6 | $30M | 350k | 84.87 | |
| Veracyte (VCYT) | 4.1 | $22M | 3.3M | 6.53 | |
| Ascendis Pharma A S (ASND) | 4.0 | $21M | 531k | 40.06 | |
| Argenx Se (ARGX) | 3.9 | $20M | 323k | 63.14 | |
| Viewray (VRAYQ) | 3.6 | $19M | 2.0M | 9.26 | |
| Kadmon Hldgs | 3.4 | $18M | 4.9M | 3.62 | |
| IRIDEX Corporation (IRIX) | 2.9 | $15M | 2.0M | 7.62 | |
| Chembio Diagnostics | 2.7 | $14M | 1.7M | 8.20 | |
| Intec Pharma | 2.6 | $14M | 2.7M | 5.15 | |
| Zogenix | 2.3 | $12M | 300k | 40.05 | |
| Edge Therapeutics | 1.7 | $8.8M | 944k | 9.37 | |
| Catalyst Biosciences | 1.2 | $6.1M | 450k | 13.64 | |
| Seattle Genetics | 1.1 | $5.9M | 110k | 53.50 | |
| Avexis | 1.1 | $5.9M | 53k | 110.66 | |
| Evolent Health (EVH) | 1.1 | $5.6M | 453k | 12.30 | |
| ACADIA Pharmaceuticals (ACAD) | 1.0 | $5.1M | 170k | 30.11 | |
| Momenta Pharmaceuticals | 0.9 | $5.0M | 360k | 13.95 | |
| iShares FTSE/Xinhua China 25 Index (FXI) | 0.9 | $4.6M | 100k | 46.17 | |
| BioCryst Pharmaceuticals (BCRX) | 0.8 | $4.4M | 900k | 4.91 | |
| CAS Medical Systems | 0.8 | $4.0M | 5.2M | 0.77 | |
| Nektar Therapeutics (NKTR) | 0.7 | $3.9M | 66k | 59.73 | |
| Nabriva Therapeutics | 0.7 | $3.5M | 580k | 5.98 | |
| Editas Medicine (EDIT) | 0.6 | $3.2M | 104k | 30.72 | |
| Global Blood Therapeutics In | 0.6 | $3.1M | 80k | 39.35 | |
| Mirati Therapeutics | 0.5 | $2.8M | 155k | 18.25 | |
| Rockwell Medical Technologies | 0.5 | $2.6M | 440k | 5.82 | |
| Loxo Oncology | 0.5 | $2.5M | 30k | 84.17 | |
| Fennec Pharmaceuticals (FENC) | 0.5 | $2.5M | 250k | 10.02 | |
| Agios Pharmaceuticals (AGIO) | 0.4 | $2.3M | 40k | 57.18 | |
| Aclaris Therapeutics (ACRS) | 0.4 | $2.3M | 93k | 24.66 | |
| Viveve Med | 0.4 | $2.2M | 433k | 4.97 | |
| Ultragenyx Pharmaceutical (RARE) | 0.4 | $2.1M | 46k | 46.37 | |
| Valeant Pharmaceuticals Int | 0.4 | $2.1M | 100k | 20.78 | |
| OraSure Technologies (OSUR) | 0.4 | $1.9M | 100k | 18.86 | |
| Crispr Therapeutics (CRSP) | 0.3 | $1.9M | 80k | 23.48 | |
| AMAG Pharmaceuticals | 0.3 | $1.8M | 133k | 13.25 | |
| Juno Therapeutics | 0.3 | $1.7M | 37k | 45.70 | |
| D Stemline Therapeutics | 0.3 | $1.6M | 105k | 15.60 | |
| Intellia Therapeutics (NTLA) | 0.3 | $1.7M | 86k | 19.22 | |
| Exelixis (EXEL) | 0.3 | $1.5M | 50k | 30.40 | |
| Neos Therapeutics | 0.3 | $1.4M | 141k | 10.20 | |
| Invitae (NVTAQ) | 0.3 | $1.4M | 152k | 9.08 | |
| Teladoc (TDOC) | 0.3 | $1.4M | 40k | 34.85 | |
| Alimera Sciences | 0.2 | $1.3M | 974k | 1.33 | |
| Five Prime Therapeutics | 0.2 | $1.2M | 53k | 21.92 | |
| Medicines Company | 0.2 | $1.1M | 40k | 27.35 | |
| Immune Design | 0.2 | $1.1M | 274k | 3.90 | |
| Atara Biotherapeutics (ATRA) | 0.2 | $996k | 55k | 18.11 | |
| Glaukos (GKOS) | 0.1 | $795k | 31k | 25.65 | |
| Evertec (EVTC) | 0.1 | $751k | 55k | 13.65 | |
| Amicus Therapeutics (FOLD) | 0.1 | $632k | 44k | 14.40 | |
| MiMedx (MDXG) | 0.1 | $631k | 50k | 12.62 | |
| Spark Therapeutics | 0.1 | $514k | 10k | 51.40 | |
| Mannkind (MNKD) | 0.1 | $400k | 173k | 2.32 | |
| AVEO Pharmaceuticals | 0.1 | $380k | 136k | 2.79 | |
| Lexicon Pharmaceuticals (LXRX) | 0.1 | $321k | 33k | 9.88 | |
| Transenterix | 0.0 | $203k | 105k | 1.93 | |
| Tg Therapeutics (TGTX) | 0.0 | $82k | 10k | 8.20 | |
| Oncobiologics | 0.0 | $38k | 29k | 1.31 |
